We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Median Technologies SA (ALMDT) Ordinary Shares EUR0.05

Sell:€10.70 Buy:€11.10 Change: €0.58 (5.62%)
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
Change: €0.58 (5.62%)
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
Change: €0.58 (5.62%)
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Median Technologies SA is a France-based company that publishes software for the diagnosis and monitoring of cancer patients. The Company develops lesion management solutions (LMS) to objectively measure and track cancerous or suspicious lesions, distribute a standardized oncologic report and centralize the lesion information for multidisciplinary review. The LMS line includes such products as LMS-Lung, a clinical application for the detection, evaluation and follow-up of lesions identified in CT images covering the chest; LMS-Track, a clinical application for the follow-up of oncology patients; and LMS-Liver, a clinical application for the initial evaluation and the follow-up of liver metastases and any other lesions identified in CT images covering the liver. The Company operates one subsidiary, Median Technologies Inc, based in the United States.

Contact details

Les Deux Arcs - Batiment B 1800
Route des Cretes
+33 (4) 93333777

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€159.44 million
Shares in issue:
15.45 million
Health Care Technology
Euronext Paris

Key personnel

  • Oran Muduroglu
    Chairman of the Board
  • Fredrik Brag
    Chief Executive Officer, Director
  • Jean-Christophe Montigny
    Chief Financial Officer
  • Nohza Boujemaa
    Chief Science and Innovation Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.